HighTower Advisors’s Amicus Therapeutics FOLD Stock Holding History

HighTower Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-2,000	Closed	-$2K	–	2096
2015 Q4	$2K	Buy	+2,000	New	+$18K	﹤0.01%	2019

Other funds holding FOLD

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

HighTower Advisors's FOLD Position: Q2 2019 in Review

HighTower Advisors sold out of Amicus Therapeutics (FOLD) in Q2 2019, closing a stake of 22,121 shares — an estimated $304K sold.

HighTower Advisors first reported a position in FOLD in Q4 2014 and held it in 8 quarters. The position peaked at $441K in Q2 2017. 206 funds tracked by Wall St. Rank hold FOLD as of Q2 2019.

HighTower Advisors reported no remaining Amicus Therapeutics position as of Q2 2019 after selling out during the quarter.
HighTower Advisors sold 22,121 Amicus Therapeutics shares in Q2 2019, an estimated $304K.
HighTower Advisors first reported a position in Amicus Therapeutics in Q4 2014 and held it in 8 quarters.
HighTower Advisors's Amicus Therapeutics position peaked at $441K in Q2 2017.
206 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2019.

Based on HighTower Advisors's 13F filing for Q2 2019, filed 13 Aug 2019.